DCM
CADX

Driehaus Capital Management’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Driehaus Capital Management’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-44,546
Closed -$304K – 575
2013
Q2 		$304K Buy
+44,546
New +$310K 0.01% 412

Other funds holding CADX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Driehaus Capital Management's CADX Position: Q3 2013 in Review

Driehaus Capital Management sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q3 2013, closing a stake of 44,546 shares — an estimated $304K sold.

Driehaus Capital Management first reported a position in CADX in Q2 2013 and held it in 1 quarter. The position peaked at $304K in Q2 2013. 90 funds tracked by Wall St. Rank hold CADX as of Q3 2013.

  • Driehaus Capital Management reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q3 2013 after selling out during the quarter.
  • Driehaus Capital Management sold 44,546 CADENCE PHARMACEUTICALS, INC COM STK shares in Q3 2013, an estimated $304K.
  • Driehaus Capital Management first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 1 quarter.
  • Driehaus Capital Management's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $304K in Q2 2013.
  • 90 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q3 2013.

Based on Driehaus Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.